



ACCESS TO QUALITY AFFORDABLE MEDICINES

*Press release*

**Quality Chemical Industries Limited rebrands following Cipla's increased shareholding**

***KAMPALA-July 16, 2014:*** Quality Chemical Industries Limited (QCIL), East Africa's leading pharmaceutical company producing quality low-cost ARV's and antimalarial has announced a new identity.

Following Cipla's increased shareholding in QCIL, the company received a new operating certificate from Uganda's Ass. Registrar of Companies dated March 24, 2014 under the name, **Cipla Quality Chemical Industries Limited (CiplaQCIL)**.

CiplaQCIL has consequently unveiled a new Logo, branding guidelines, and yet to be launched website: [www.ciplaqcil.co.ug](http://www.ciplaqcil.co.ug), in an effort to streamline its official communications and visibility.

Commenting on the new identity, Mr. Nevin Bradford, Chief Executive Officer, CiplaQCIL says: "The identity transformation is part of the changes agreed on following Cipla's increased shareholding in the company. The Board of Directors found it appropriate to rebrand the company to reflect the current ownership/shareholding structure, and more specifically to reflect Cipla's global identity and vision that 'None shall be denied access to affordable, quality medicines'.

"Since taking office in December last year, part of my remit has been to further inculcate the Cipla name, vision and culture here at QCIL. We are excited about the new company name which emphasizes our relationship with Cipla as we continue to produce high quality, affordable drugs in the therapeutic areas most needed in our region."

---

---

**About CiplaQCIL:**

Cipla Quality Chemical Industries Limited (CiplaQCIL) is a state-of-the-art pharmaceutical plant approved by the World Health Organization to manufacture Anti-retroviral (ARVs) and anti-malarial drugs.

Founded in June 2005, QCIL began as a joint venture between Quality Chemicals Ltd. (QCL) - a leading importer and distributor of pharmaceutical drugs in Uganda, and Cipla Ltd., a global leader in manufacture of generic medicines. The joint venture later attracted Capitalworks SSA 1 of Mauritius at 14.4% and TLG Capital of United Kingdom at 12.5%, leaving CIPLA and QCL at 36.55% each. With the new shareholding, Cipla now owns 51.05% of the shareholding with QCL holding onto 22%.

Currently, CiplaQCIL produces various first-line fixed-dose combinations of ARVs-Duovir-N, Duovir, Duomune; single dose Efavir and Nevimune plus Lumartem-an antimalarial drug.

### **About Cipla**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2012/13 was 1.5 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognizes its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

***For more information, please contact Irene Nabusoba, the Public Relations Executive on:***

***Tel; 0776936669***

***Email; nabusoba@qcil.co.ug or frontdesk@qcil.co.ug***